JCAR-018 is under clinical development by Syncopation Life Sciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect JCAR-018’s likelihood of approval (LoA) and phase transition for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) took place on 18 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 18 Feb 2022 decreased JCAR-018’s LoA and PTSR for Non-Hodgkin Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JCAR-018 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

JCAR-018 overview

JCAR-018 is under development for the treatment of pediatric, young and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). It is a second generation m971 mAb-derived chimeric antigen receptors (CARs) T-cells transduced with lentivirus targeting CD22. It is administered through intravenous route as an infusion. The therapeutic candidate is developed based on the chimeric antigen receptor (CAR) technology.

Syncopation Life Sciences overview

Syncopation Life Sciences discovers and develops adoptive cell therapies for the treatment of cancer. The company utilizes its proprietary Syncopation insights and platform, to advance primary mechanisms of resistance in chimeric antigen receptor t-cell (CAR-T) therapies; and develops pipeline programs targeting cancer. Syncopation Life Sciences with new engineering technologies is developing the next generation of adoptive cell therapies. The company funding partners include Samsara Biocaptial, Emerson Collective and Red Tree Venture Capital. Syncopation Life Sciences is headquartered in San Mateo, California, the US.

Quick View JCAR-018 LOA Data

Report Segments
  • Innovator
Drug Name
  • JCAR-018
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.